Table 2. Paclitaxel/Platinum Combinations Versus Comparator Arms in Trials
| Trial | Treatment Regimens | No. of Patients | % Early Crossover | Progression-free Survival (mo) | Overall Survival (mo) |
| GOG-132 | Paclitaxel (135 mg/m2, 24 h) and cisplatin (75 mg/m2) | 201 | 22% | 14.2 | 26.6 |
| Cisplatin (100 mg/m2) | 200 | 40% | 16.4 | 30.2 | |
| Paclitaxel (200 mg/m2, 24 h) | 213 | 23% | 11.2a | 26 | |
| MRC-ICON3[20] | Paclitaxel (175 mg/m2, 3 h) and carboplatin AUC 6 | 478 | 23% | 17.3 | 36.1 |
| Carboplatin AUC 6 | 943 | 25% | 16.1 | 35.4 | |
| Paclitaxel (175 mg/m2, 3 h) and carboplatin AUC 6 | 232 | 23% | 17 | 40 | |
| Cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2) and cisplatin (50 mg/m2) | 421 | 20% | 17 | 40 | |
| GOG-111[21] | Paclitaxel (135 mg/m2, 24 h) and cisplatin (75 mg/m2) | 184 | None | 18 | 38 |
| Cyclophosphamide (750 mg/m2) and cisplatin (75 mg/m2) | 202 | None | 13a | 24a | |
| EORTC-55931[22] | Paclitaxel (175 mg/m2, 3 h) and cisplatin (75 mg/m2) | 162 | None | 15.5 | 35.6 |
| Cyclophosphamide (750 mg/m2) and cisplatin (75 mg/m2) | 161 | 4% | 11.5a | 25.8a |
| AUC = area under the curve. | |||||
| aStatistically inferior result (P < .001–< .05). |
References
- The International Collaborative Ovarian Neoplasm Group.: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360 (9332): 505-15, 2002. [PUBMED Abstract]
- du Bois A, Lück HJ, Meier W, et al.: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (17): 1320-9, 2003. [PUBMED Abstract]
- Neijt JP, Engelholm SA, Tuxen MK, et al.: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18 (17): 3084-92, 2000. [PUBMED Abstract]
